Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9312513 | 1.00 | PDE4A (0.50) | PDE4AUSP2SLCO1B1SLC1A3SLC1A2 | |
| SCHEMBL22123640 | 1.00 | PDE4A (0.50) | PDE4AUSP2SLCO1B1SLC1A3SLC1A2 | |
| SCHEMBL5308623 | 1.00 | PDE4A (0.50) | PDE4AUSP2SLCO1B1SLC1A3SLC1A2 | |
| SCHEMBL14556019 | 1.00 | PDE4A (0.50) | PDE4AUSP2SLCO1B1SLC1A3SLC1A2 | |
| SCHEMBL2933990 | 0.94 | PDE4A (0.54) | PDE4AUSP2SLCO1B1SLC1A3SLC1A2 | |
| SCHEMBL15049970 | 0.92 | PDE4A (0.52) | PDE4AUSP2SLCO1B1SLC1A3SLC1A2 | |
| SCHEMBL8680823 | 0.92 | PDE4A (0.52) | PDE4AUSP2SLCO1B1SLC1A3SLC1A2 | |
| SCHEMBL15841657 | 0.86 | SLC1A3 (0.48) | PDE4AUSP2SLCO1B1SLC1A3SLC1A2 | |
| SCHEMBL15841459 | 0.86 | SLC1A3 (0.48) | PDE4AUSP2SLCO1B1SLC1A3SLC1A2 | |
| SCHEMBL379304 | 0.86 | SLC1A3 (0.48) | PDE4AUSP2SLCO1B1SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223392-A1 | HYDROPHILIZED POLYDIORGANOSILOXANE VINYLIC CROSSLINKERS AND USES THEREOF | ALCON INC (CH) | 2025-07-10 | — | — | US | disclosed |
| US-12286501-B2 | Hydrophilized polydiorganosiloxane vinylic crosslinkers and uses thereof | ALCON INC. (CH) | 2025-04-29 | — | — | US | disclosed |
| US-20250059330-A1 | SILICONE HYDROGEL CONTACT LENSES | ALCON INC (CH) | 2025-02-20 | — | — | US | disclosed |
| EP-4481478-A2 | SILICONE HYDROGEL CONTACT LENSES | Alcon Inc. (CH) | 2024-12-25 | — | — | EP | disclosed |
| US-12162987-B2 | Silicone hydrogel contact lenses | ALCON INC. (CH) | 2024-12-10 | — | — | US | disclosed |
| EP-4235274-B1 | SILICONE HYDROGEL CONTACT LENSES | ALCON INC (CH) | 2024-10-09 | — | — | EP | disclosed |
| US-20240254269-A1 | HYDROPHILIZED POLYDIORGANOSILOXANE VINYLIC CROSSLINKERS AND USES THEREOF | ALCON INC. (CH) | 2024-08-01 | — | — | US | disclosed |
| US-20240018309-A1 | SILICONE HYDROGEL CONTACT LENSES | ALCON INC. (CH) | 2024-01-18 | — | — | US | disclosed |
| US-11802182-B2 | Silicone hydrogel contact lenses | ALCON INC. (CH) | 2023-10-31 | — | — | US | disclosed |
| EP-4235274-A2 | SILICONE HYDROGEL CONTACT LENSES | Alcon Inc. (CH) | 2023-08-30 | — | — | EP | disclosed |
| EP-3390498-A1 | HYDROPHILIZED POLYDIORGANOSILOXANE VINYLIC CROSSLINKERS AND USES THEREOF | Novartis AG (CH) | 2018-10-24 | — | — | EP | disclosed |
| US-10081697-B2 | Hydrophilized polydiorganosiloxane vinylic crosslinkers and uses thereof | NOVARTIS AG (CH) | 2018-09-25 | — | — | US | disclosed |
| WO-2017103790-A1 | HYDROPHILIZED POLYDIORGANOSILOXANE VINYLIC CROSSLINKERS AND USES THEREOF | NOVARTIS AG (CH) | 2017-06-22 | — | — | WO | disclosed |
| US-20170166673-A1 | HYDROPHILIZED POLYDIORGANOSILOXANE VINYLIC CROSSLINKERS AND USES THEREOF | ALCON INC. (CH) | 2017-06-15 | — | — | US | disclosed |
| US-20090299093-A1 | Preparation of Gamma-Amino Acids Having Affinity for The Alpha-2-Delta Protein | PFIZER INC. | 2009-12-03 | — | — | US | disclosed |
| EP-2017259-A2 | Preparation of gamma-amino acids having affinity for the alpha-2-delta protein | Pfizer Products Inc. (US) | 2009-01-21 | — | — | EP | disclosed |
| EP-1973867-A1 | PREPARATION OF GAMMA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | Pfizer Products Inc. (US) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007072159-A1 | PREPARATION OF GAMMA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | PFIZER PRODUCTS INC. (US) | 2007-06-28 | — | — | WO | disclosed |
| US-20070141684-A1 | Preparation of gamma-amino acids having affinity for the alpha-2-delta protein | PFIZER INC | 2007-06-21 | — | — | US | disclosed |
| US-4448912-A | QUATERNIZATION WITH PRIMARY AND/OR SECONDARY AMINE AND ACID | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070141684-A1 | Preparation of gamma-amino acids having affinity for the alpha-2-delta protein | SCN2A, CACNG2, SCN1A | PDE4A 4199/4885USP2 2782/4885SLCO1B1 3181/4885 |
| US-20090299093-A1 | Preparation of Gamma-Amino Acids Having Affinity for The Alpha-2-Delta Protein | SCN2A, CACNG2, SCN1A | PDE4A 4199/4885USP2 2782/4885SLCO1B1 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.